PFIZER INC - Research Update.

PR Newswire UK Disclose, March, 2006

 
 'Only Lipitor Has Demonstrated Significant LDL Reductions and Cardiovascular 
 Benefits for a Wide Range of Patients, With an Excellent Efficacy and Safety 
                     Profile Across the Full Dose Range' 
 
           Lipitor demonstrated plaque regression in REVERSAL trial 
 
    ATLANTA, March 13 -- In response to inquiries from the news media about the 
ASTEROID trial for Crestor presented today at the American College of 
Cardiology, Pfizer issued the following statement: 
 
    -- Only Lipitor has demonstrated significant LDL reductions and 
       cardiovascular benefits for a wide range of patients, with an excellent 
       efficacy and safety profile across the full dose range. 
 
    -- This is not the first time a statin has demonstrated plaque regression....

            
        
    
    	    
                
                
	

		

					 
            Read the rest of this article with a Free Trial at HighBeam Research.
        				
 

    		            
	
                Premium Content Partnership | 
                	HighBeam Research provides an in-depth online archive library of reference works.